ROVI leads the BioElast Consortium approved in the 2021 Call for Projects in Public-Private Collaboration of the MCIN (AEI)

The project led by Laboratorios Farmacéuticos ROVI, "Bioreactors and Biotints with heparin for the regeneration of Elastic Tissues (BioElasT)", obtains funding.


Madrid: 28 of December 2022

The project entitled “Bioreactors and Biostains with Heparin for the Regeneration of Elastic Tissues (BioElasT)”, led by Laboratorios Farmacéuticos ROVI, S.A., in collaboration with the company Regemat 3D, S.L. and the Basque Centre for Macromolecular Design and EngineeringPolymatFundazioa, University of the Basque Country Euskal Herriko Unibertsitatea and Consorcio Centro de Investigación Biomédica in Red M.P. (CIBER, has been funded by MCIN/AEI/10.13039/ 501100011033 and by the European Union-NextGenerationEU/PRTR, through the call for the 2021 Public-Private Collaboration program (CPP2021-008754).

The objective of the call for grants to public-private partnership projects is to support experimental development in cooperation between companies and research organizations, promoting the development of new technologies, the business application of new ideas and techniques; and contributing to the creation of new products and services. With this, it also seeks to facilitate the transfer of knowledge through actions that eliminate the existing barriers between the different actors in the public and private spheres and increase the dissemination and communication capacities of R+D+i to society by contributing to the fulfilment of specific objective 5 (SO5) of the State Plan for Scientific, Technical and Innovation Research for the period 2021-2023.

No votes yet
 
Related
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION (COMISIÓN NACIONAL DEL MERCADO DE VALORES) Madrid, 23 November 2022 In...
1 min
23/11/2022
ROVI reports operating revenue growth of 24% and EBITDA growth of 25% • Operating revenue increased by 24% to 575.5 million euros driven...
3 min
04/11/2022
On his visit to the plant, which is ready to start production as soon as the authorisation from the Spanish Agency of Medicines and...
4 min
24/10/2022